Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.38 |
| ▸ | ALB | P02768 | 8/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | EPOR | P19235 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20980230 | 0.86 | ALB (0.38) | ALBFOLH1 | |
| SCHEMBL26346638 | 0.84 | GLP1R (0.40) | GLP1RALBTSHREPORFOLH1 | |
| SCHEMBL25944862 | 0.84 | ALB (0.36) | GLP1RALB | |
| SCHEMBL26759929 | 0.84 | MEN1 (0.35) | — | |
| SCHEMBL22314737 | 0.81 | ACHE (0.35) | — | |
| SCHEMBL25602406 | 0.80 | TSHR (0.38) | GLP1RTSHR | |
| SCHEMBL25771633 | 0.80 | TSHR (0.38) | GLP1RTSHR | |
| SCHEMBL26759934 | 0.79 | ADRB2 (0.33) | — | |
| SCHEMBL25128699 | 0.78 | TSHR (0.42) | GLP1RALBTSHRFOLH1 | |
| SCHEMBL27312937 | 0.78 | TSHR (0.42) | GLP1RALBTSHRFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357342-A1 | MODIFIED IL-18 POLYPEPTIDES | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-11-09 | — | — | US | disclosed |
| US-20230355795-A1 | IMMUNE ANTIGEN SPECIFIC IL-18 IMMUNOCYTOKINES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355795-A1 | IMMUNE ANTIGEN SPECIFIC IL-18 IMMUNOCYTOKINES AND USES THEREOF | IL18, CD74, IL2 | GLP1R 3438/4885ALB 742/4885TSHR 1840/4885 |
| US-20230357342-A1 | MODIFIED IL-18 POLYPEPTIDES | IL18, IL2, IL36G | GLP1R 1593/4885ALB 1577/4885TSHR 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.